Previous close | 255.45 |
Open | 256.61 |
Bid | 247.38 x 1000 |
Ask | 258.87 x 1300 |
Day's range | 252.51 - 259.10 |
52-week range | 176.36 - 292.75 |
Volume | |
Avg. volume | 1,646,788 |
Market cap | 65.747B |
Beta (5Y monthly) | 0.61 |
PE ratio (TTM) | 31.01 |
EPS (TTM) | 8.34 |
Earnings date | 27 Apr 2022 - 02 May 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 293.15 |
You may be spending a little more time than you'd like these days thinking about a future market crash. But instead of letting the recent stock-market decline scare us, we should let it help us: Let's use it as a reminder that market corrections and crashes will happen.
Here's why they picked Exelixis (NASDAQ: EXEL), Moderna (NASDAQ: MRNA), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (Exelixis): If you're looking to hit a home run with an investment, it's important to look for a balance of a modest valuation and promising growth. One underrated stock that possesses all these features is cancer-fighting company Exelixis, which has a market cap of around $5.4 billion.
Alibaba, McDonald, Advanced Micro Devices, Abbott Laboratories, and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.